CompletedPhase 1

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

United States, Denmark, Germany14 participantsStarted 2024-10-22

Plain-language summary

This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Serum creatinine level
✕. Total bilirubin, aspartate aminotransferase or alanine aminotransferase values
✕. Hematological or coagulation values outside the normal reference range

To Determine the impact of multiple doses of RCT1100 on MCC

Timeframe: Baseline through Week 12

NCT IDNCT06633757

SponsorReCode Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-30